Sugi Predict

Sugi Predict / Compounds / SCHEMBL554235

SCHEMBL554235

SCHEMBL554235

CC(C)(C)[Si](OCCN1CCNCC1)(c1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 3/20 0.49
▸ LTA4H P09960 1/20 0.46
▸ CHRM2 P08172 1/20 0.45
▸ CHRM4 P08173 1/20 0.45
▸ CHRM5 P08912 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ CHRM3 P20309 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ SMYD2 Q9NRG4 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22559425 0.94 SIGMAR1 (0.44) SIGMAR1LTA4HCHRM2CHRM4CHRM5
SCHEMBL28735718 0.87 MEN1 (0.49) LTA4HCHRM2CHRM1ALDH1A1MEN1
SCHEMBL28735726 0.79 HRH3 (0.48) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL31737874 0.78 MEN1 (0.50) LTA4HCHRM2CHRM4CHRM5CHRM1
SCHEMBL31680935 0.78 CARM1 (0.54) SIGMAR1CHRM2CHRM3SMN1; SMN2SMYD2
SCHEMBL10759034 0.77 SMYD2 (0.43) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL31633883 0.76 HTR1A (0.39) SMYD2
SCHEMBL31633863 0.76 HTR1A (0.39) SMYD2
SCHEMBL28917486 0.76 SMYD2 (0.43) SMN1; SMN2SMYD2TDP1
SCHEMBL31737789 0.76 SMYD2 (0.41) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 — — US disclosed
US-RE50643-E1 Benzamide compounds RECURIUM IP HOLDINGS, LLC (US) 2025-10-21 — — US disclosed
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 — — US disclosed
EP-4556469-A1 BENZAMIDE COMPOUNDS Recurium IP Holdings, LLC (US) 2025-05-21 — — EP disclosed
WO-2025067411-A1 NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京普祺医药科技股份有限公司 2025-04-03 — — WO disclosed
EP-3740487-B1 BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV RECURIUM IP HOLDINGS LLC (US) 2025-01-08 — — EP disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
EP-4182308-B1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 — — EP disclosed
US-20240180899-A1 BENZAMIDE COMPOUNDS RECURIUM IP HOLDINGS, LLC 2024-06-06 — — US disclosed
CN-118084904-A Benzamide compounds 里科瑞尔姆IP控股有限责任公司 2024-05-28 — — CN disclosed
US-20150328239-A1 Chemical Compounds ASTRAZENECA AB (SE) 2015-11-19 — — US disclosed
US-9018381-B2 Chemical compounds ASTRAZENECA AB (SE) 2015-04-28 — — US disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 — — US disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 — — US disclosed
EP-2822656-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE Institute of Cancer Research: Royal Cancer Hospital (The) (GB) 2015-01-14 — — EP disclosed
US-20130310344-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ASTRAZENECA AB (UK) 2013-11-21 — — US disclosed
WO-2013132253-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2013-09-12 — — WO disclosed
EP-2601177-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS AstraZeneca AB (SE) 2013-06-12 — — EP disclosed
US-20120035134-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 — — US disclosed
WO-2012017251-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ASTRAZENECA AB (SE) 2012-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE TNKS, TNKS2, PARP11 SIGMAR1 4456/4885LTA4H 4239/4885CHRM2 4832/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 SIGMAR1 1725/4885LTA4H 1535/4885CHRM2 3573/4885
US-20120035134-A1 CHEMICAL COMPOUNDS BCL2, BCL2L1, BAX SIGMAR1 3899/4885LTA4H 3871/4885CHRM2 4830/4885
US-20240180899-A1 BENZAMIDE COMPOUNDS MKI67, TMBIM6, HDAC1 SIGMAR1 3721/4885LTA4H 1683/4885CHRM2 4781/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 SIGMAR1 2353/4885LTA4H 1613/4885CHRM2 3849/4885
US-20150328239-A1 Chemical Compounds BCL2, BCL2L1, BAX SIGMAR1 3899/4885LTA4H 3871/4885CHRM2 4830/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 SIGMAR1 3083/4885LTA4H 2012/4885CHRM2 1260/4885
US-20130310344-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BCL2, BAX, BCLAF1 SIGMAR1 4285/4885LTA4H 3695/4885CHRM2 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.